Teva Pharmaceutical Industries Limited (TEVA) Quarterly Income Statement

120+ quarters historyFree accessUpdated daily

Teva Pharmaceutical Industries Limited (TEVA) quarterly income statement — complete revenue, gross profit & net income history

Quarterly statement

TEVA Income Statement

Teva Pharmaceutical Industries Limited (TEVA) annual income statement — 30-year revenue, gross profit & net income history

Annual Quarterly

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23	Q1'23	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21

Sales/Revenue	4.39B	4.14B	3.98B	4.71B	4.48B	4.18B	3.89B	4.23B	4.33B	4.16B	3.82B	4.46B	3.85B	3.88B	3.66B	3.88B	3.6B	3.79B	3.66B	4.1B
Revenue Growth %	-1.9%	-0.81%	2.31%	11.4%	3.44%	0.29%	1.89%	-5.12%	12.49%	7.37%	4.32%	14.78%	7.09%	2.43%	0%	-5.29%	-7.51%	-3.17%	-8.06%	-7.93%
Cost of Goods Sold	1.96B	1.99B	2.01B	2.06B	2.18B	2.07B	2.01B	2.11B	2.18B	2.14B	2.05B	2.04B	2B	2.08B	2.08B	2.11B	1.93B	1.99B	1.92B	2.05B
COGS % of Revenue	44.48%	48.02%	50.51%	43.64%	48.57%	49.66%	51.76%	49.87%	50.4%	51.39%	53.63%	45.79%	51.92%	53.69%	56.79%	54.42%	53.57%	52.61%	52.47%	50%
Gross Profit	2.44B	2.15B	1.97B	2.66B	2.3B	2.1B	1.88B	2.12B	2.15B	2.02B	1.77B	2.42B	1.85B	1.8B	1.58B	1.77B	1.67B	1.79B	1.74B	2.05B
Gross Margin %	55.52%	51.98%	49.54%	56.38%	51.43%	50.34%	48.24%	50.13%	49.6%	48.61%	46.37%	54.21%	48.08%	46.31%	43.21%	45.58%	46.43%	47.39%	47.53%	50%
Gross Profit Growth %	5.9%	2.43%	5.06%	25.28%	7.26%	3.85%	5.99%	-12.25%	16.05%	12.69%	11.95%	36.5%	10.9%	0.11%	-9.08%	-13.66%	-6.97%	-4.22%	-7.35%	0.1%
Operating Expenses	1.73B	2B	1.32B	2.35B	1.42B	1.65B	1.36B	2.15B	2.2B	2.03B	1.99B	1.66B	1.51B	2.45B	1.59B	2.63B	1.25B	2.74B	2.45B	1.97B
OpEx % of Revenue	39.27%	48.38%	33.11%	49.99%	31.74%	39.44%	34.9%	50.82%	50.77%	48.73%	52.08%	37.24%	39.14%	63.18%	43.57%	67.6%	34.77%	72.45%	67%	48.1%
Selling, General & Admin	1.01B	1.03B	1B	1.12B	973M	959M	919M	952M	924M	939M	886M	902M	844M	910M	842M	837M	822M	907M	880M	908M
SG&A % of Revenue	22.91%	24.96%	25.12%	23.77%	21.72%	22.96%	23.62%	22.51%	21.33%	22.55%	23.2%	20.24%	21.92%	23.47%	23%	21.56%	22.87%	23.96%	24.04%	22.15%
Research & Development	297M	250M	222M	267M	256M	244M	247M	271M	240M	269M	242M	234M	253M	275M	253M	210M	175M	228M	225M	244M
R&D % of Revenue	6.76%	6.04%	5.58%	5.67%	5.71%	5.84%	6.35%	6.41%	5.54%	6.46%	6.34%	5.25%	6.57%	7.09%	6.91%	5.41%	4.87%	6.02%	6.15%	5.95%
Other Operating Expenses	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K	1000K
Operating Income	714M	149M	652M	300M	882M	455M	519M	-29M	-51M	-5M	-218M	756M	344M	-654M	-13M	-855M	419M	-949M	-713M	78M
Operating Margin %	16.25%	3.6%	16.38%	6.37%	19.69%	10.9%	13.34%	-0.69%	-1.18%	-0.12%	-5.71%	16.96%	8.94%	-16.86%	-0.36%	-22.02%	11.66%	-25.07%	-19.48%	1.9%
Operating Income Growth %	-19.05%	-67.25%	25.63%	1134.48%	1829.41%	9200%	338.07%	-103.84%	-114.83%	99.24%	-1576.92%	188.42%	-17.9%	31.09%	98.18%	-1196.15%	-32.74%	-263.06%	-264.29%	-80.79%
EBITDA	959M	390M	891M	560M	1.13B	706M	763M	240M	208M	254M	54M	1.02B	627M	-354M	291M	-549M	740M	-591M	-390M	398M
EBITDA Margin %	21.82%	9.42%	22.38%	11.89%	25.25%	16.91%	19.61%	5.68%	4.8%	6.1%	1.41%	22.93%	16.29%	-9.13%	7.95%	-14.14%	20.58%	-15.61%	-10.65%	9.71%
EBITDA Growth %	-15.21%	-44.76%	16.78%	133.33%	443.75%	177.95%	1312.96%	-76.52%	-66.83%	171.75%	-81.44%	286.16%	-15.27%	40.1%	174.62%	-237.94%	-22.27%	-166.63%	-148.15%	-50.31%
D&A (Non-Cash Add-back)	245M	241M	239M	260M	249M	251M	244M	269M	259M	259M	272M	266M	283M	300M	304M	306M	321M	358M	323M	320M
EBIT	300M	-260M	638M	372M	855M	406M	709M	893M	-52M	-13M	-217M	1.25B	344M	670M	499M	-892M	418M	651M	-713M	-89M
Net Interest Income	0	-200M	-201M	-292M	-209M	-203M	-225M	763M	-272M	-241M	-250M	-260M	-280M	-268M	-260M	-280.25M	-252M	-211M	-258M	-180M
Interest Income	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Interest Expense	0	200M	201M	292M	209M	203M	225M	-763M	272M	241M	250M	260M	280M	268M	260M	280.25M	252M	211M	258M	180M
Other Income/Expense	-414M	-604M	-216M	-209M	-234M	-251M	-225M	-218M	-270M	-239M	-253M	-248M	-280M	-237M	-221M	-245M	-254M	1.59B	-237M	-253M
Pretax Income	300M	-455M	436M	91M	648M	204M	294M	-247M	-321M	-244M	-471M	508M	64M	-891M	-234M	-1.1B	165M	641M	-950M	-175M
Pretax Margin %	6.83%	-10.98%	10.95%	1.93%	14.46%	4.89%	7.56%	-5.84%	-7.41%	-5.86%	-12.33%	11.4%	1.66%	-22.98%	-6.39%	-28.33%	4.59%	16.93%	-25.95%	-4.27%
Income Tax	66M	121M	67M	-390M	214M	-78M	74M	28M	69M	630M	-52M	41M	-12M	16M	19M	154M	107M	900M	2M	-24M
Effective Tax Rate %	22%	-26.59%	15.37%	-428.57%	33.02%	-38.24%	25.17%	-11.34%	-21.5%	-258.2%	11.04%	8.07%	-18.75%	-1.8%	-8.12%	-14%	64.85%	140.41%	-0.21%	13.71%
Net Income	233M	-576M	369M	480M	433M	282M	214M	-217M	-437M	-846M	-139M	463M	69M	-872M	-220M	-1.22B	56M	-232M	-955M	-159M
Net Margin %	5.3%	-13.91%	9.27%	10.19%	9.67%	6.75%	5.5%	-5.13%	-10.09%	-20.32%	-3.64%	10.39%	1.79%	-22.49%	-6.01%	-31.44%	1.56%	-6.13%	-26.09%	-3.88%
Net Income Growth %	-46.19%	-304.26%	72.43%	321.2%	199.08%	133.33%	253.96%	-146.87%	-733.33%	2.98%	36.82%	137.92%	23.21%	-275.86%	76.96%	-667.92%	-80.82%	-212.08%	-1340.26%	-206%
Net Income (Continuing)	234M	-576M	369M	481M	434M	282M	220M	-275M	-390M	-874M	-419M	467M	76M	-907M	-253M	-1.25B	58M	-259M	-952M	-151M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Minority Interest	5M	4M	4M	4M	4M	7M	7M	347M	319M	204M	265M	620M	582M	656M	751M	794M	751M	791M	916M	966M
EPS (Diluted)	0.20	-0.49	0.31	0.41	0.37	0.24	0.18	-0.19	-0.39	-0.74	-0.13	0.41	0.07	-0.77	-0.20	-1.10	0.05	-0.21	-0.86	-0.14
EPS Growth %	-45.95%	-304.17%	72.22%	315.79%	194.87%	132.43%	238.46%	-146.34%	-653.19%	3.9%	35%	137.27%	41%	-266.67%	76.74%	-685.71%	-80.77%	-210.53%	-1328.57%	-200%
EPS (Basic)	0.20	-0.49	0.32	0.42	0.38	0.25	0.19	-0.19	-0.39	-0.74	-0.13	0.41	0.07	-0.77	-0.20	-1.10	0.05	-0.21	-0.86	-0.14
Diluted Shares Outstanding	1.18B	1.18B	1.18B	1.17B	1.16B	1.16B	1.16B	1.13B	1.13B	1.13B	1.12B	1.14B	1.14B	1.12B	1.11B	1.11B	1.12B	1.11B	1.11B	1.1B
Basic Shares Outstanding	1.17B	1.17B	1.16B	1.15B	1.15B	1.15B	1.14B	1.13B	1.13B	1.13B	1.12B	1.12B	1.12B	1.12B	1.11B	1.11B	1.11B	1.11B	1.11B	1.1B
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-